Mosliciguat - Bayer
Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Bayer
- Class Amines; Benzoic acids; Biphenyl compounds; Cardiovascular therapies; Chlorobenzenes; Fluorinated hydrocarbons; Phenyl ethers; Quinolines; Small molecules; Urologics
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders; Kidney disorders
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Cardiovascular-disorders in Germany
- 28 Sep 2024 No recent reports of development identified for phase-I development in Kidney-disorders in Germany
- 07 Sep 2021 Chemical structure information added